Two Sigma Advisers LP Grows Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Two Sigma Advisers LP boosted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 452.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 126,400 shares of the company's stock after purchasing an additional 103,500 shares during the quarter. Two Sigma Advisers LP owned approximately 0.27% of 4D Molecular Therapeutics worth $704,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in 4D Molecular Therapeutics during the 4th quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at about $50,000. PNC Financial Services Group Inc. raised its position in shares of 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after purchasing an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after purchasing an additional 9,737 shares in the last quarter. Finally, Virtus ETF Advisers LLC grew its position in 4D Molecular Therapeutics by 173.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock worth $58,000 after purchasing an additional 6,560 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Stock Up 11.3%

Shares of FDMT stock traded up $0.44 on Friday, hitting $4.35. The company had a trading volume of 670,178 shares, compared to its average volume of 826,429. 4D Molecular Therapeutics, Inc. has a twelve month low of $2.24 and a twelve month high of $28.93. The firm has a market cap of $201.51 million, a P/E ratio of -1.53 and a beta of 2.84. The company has a 50-day moving average price of $3.28 and a 200-day moving average price of $4.65.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). Equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on FDMT shares. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Barclays reduced their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group dropped their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Weiss Ratings reissued a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a report on Saturday, May 24th. Finally, Bank of America reduced their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.